These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 9681527)
1. Validation of a model predicting enrollment status in a chemoprevention trial for breast cancer. Yeomans Kinney A; Vernon SW; Shui W; Weber DV; Schell M; Vogel VG Cancer Epidemiol Biomarkers Prev; 1998 Jul; 7(7):591-5. PubMed ID: 9681527 [TBL] [Abstract][Full Text] [Related]
2. The effect of physician recommendation on enrollment in the Breast Cancer Chemoprevention Trial. Kinney AY; Richards C; Vernon SW; Vogel VG Prev Med; 1998; 27(5 Pt 1):713-9. PubMed ID: 9808803 [TBL] [Abstract][Full Text] [Related]
3. Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users. Rondanina G; Puntoni M; Severi G; Varricchio C; Zunino A; Feroce I; Bonanni B; Decensi A J Clin Oncol; 2008 Mar; 26(9):1537-43. PubMed ID: 18349406 [TBL] [Abstract][Full Text] [Related]
4. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Melnikow J; Paterniti D; Azari R; Kuenneth C; Birch S; Kuppermann M; Nuovo J; Keyzer J; Henderson S Cancer; 2005 May; 103(10):1996-2005. PubMed ID: 15825209 [TBL] [Abstract][Full Text] [Related]
5. Breast cancer risk in primary care: implications for chemoprevention. Lewis CL; Kinsinger LS; Harris RP; Schwartz RJ Arch Intern Med; 2004 Sep; 164(17):1897-903. PubMed ID: 15451765 [TBL] [Abstract][Full Text] [Related]
6. Decision analysis of tamoxifen for the prevention of invasive breast cancer. Grann VR; Sundararajan V; Jacobson JS; Whang W; Heitjan DF; Antman KH; Neugut AI Cancer J; 2000; 6(3):169-78. PubMed ID: 10882333 [TBL] [Abstract][Full Text] [Related]
7. Chemoprevention: drug pricing and mortality: the case of tamoxifen. Melnikow J; Kuenneth C; Helms LJ; Barnato A; Kuppermann M; Birch S; Nuovo J Cancer; 2006 Sep; 107(5):950-8. PubMed ID: 16865680 [TBL] [Abstract][Full Text] [Related]
8. Breast cancer risks and prevention: implications of the Breast Cancer Prevention Trial results. Crowell EB; Jubelirer SJ W V Med J; 2000; 96(6):598-601. PubMed ID: 11194088 [TBL] [Abstract][Full Text] [Related]
9. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts. Vogel VG Clin Cancer Res; 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233 [TBL] [Abstract][Full Text] [Related]
10. Factors related to enrollment in the breast cancer prevention trial at a comprehensive cancer center during the first year of recruitment. Yeomans-Kinney A; Vernon SW; Frankowski RF; Weber DM; Bitsura JM; Vogel VG Cancer; 1995 Jul; 76(1):46-56. PubMed ID: 8630876 [TBL] [Abstract][Full Text] [Related]
11. Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits. Brewster AM; Christo DK; Lai H; Helzlsouer K Cancer; 2005 Mar; 103(6):1147-53. PubMed ID: 15674856 [TBL] [Abstract][Full Text] [Related]
12. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118 [TBL] [Abstract][Full Text] [Related]
13. Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. Abramson N; Costantino JP; Garber JE; Berliner N; Wickerham DL; Wolmark N J Natl Cancer Inst; 2006 Jul; 98(13):904-10. PubMed ID: 16818854 [TBL] [Abstract][Full Text] [Related]
14. Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention. Goldenberg VK; Seewaldt VL; Scott V; Bean GR; Broadwater G; Fabian C; Kimler B; Zalles C; Lipkus IM Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1032-4. PubMed ID: 17507634 [TBL] [Abstract][Full Text] [Related]
15. Cancer prevention trials and primary care physicians: factors associated with recommending trial enrollment. Battaglia TA; Ash A; Prout MN; Freund KM Cancer Detect Prev; 2006; 30(1):34-7. PubMed ID: 16476525 [TBL] [Abstract][Full Text] [Related]
16. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. Bober SL; Hoke LA; Duda RB; Regan MM; Tung NM J Clin Oncol; 2004 Dec; 22(24):4951-7. PubMed ID: 15598980 [TBL] [Abstract][Full Text] [Related]
17. [Breakthrough in breast cancer chemoprevention]. Kahán Z; Thurzó L Orv Hetil; 2003 Mar; 144(13):597-603. PubMed ID: 12728784 [TBL] [Abstract][Full Text] [Related]
18. Feasibility of a telephone survey to recruit health maintenance organization members into a tamoxifen chemoprevention trial. Daly M; Seay J; Balshem A; Lerman C; Engstrom P Cancer Epidemiol Biomarkers Prev; 1992; 1(5):413-6. PubMed ID: 1305474 [TBL] [Abstract][Full Text] [Related]
19. Interest in breast cancer chemoprevention among older women. Tjia J; Micco E; Armstrong K Breast Cancer Res Treat; 2008 Apr; 108(3):435-53. PubMed ID: 17554628 [TBL] [Abstract][Full Text] [Related]
20. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis. Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]